WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...
Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The ...
It's Day 4. We recap a few impactful sessions exploring why patients – including rare disease patients and women – can't wait. Today, we close out with a look at how we can ensure the virtuous cycle ...
WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC ...
Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and ...
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...
BIO launches a new campaign to explain why we vaccinate – and why it's good for America. We have details, plus how drug companies are investing in U.S. manufacturing, news on drug prices and IP, and ...
While pharmaceuticals were spared the U.S. tariffs that shook world markets last week, the respite could be short-lived. The impact: 94% of biotech firms anticipate surging manufacturing costs from ...
John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...
WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback